{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:39:08Z","timestamp":1793457548178,"version":"4.5.0"},"reference-count":159,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance. Risk stratification tools and cytogenetic alterations help inform individualized therapeutic choices for patients in hopes of achieving long-term remissions with preserved quality of life. Unfortunately, relapses occur at different stages of the course of the disease owing to the biological heterogeneity of the disease. Addressing relapse can be complex and challenging as there are both therapy- and patient-related factors to consider. In this broad scoping review of available therapies in relapsed\/refractory multiple myeloma (RRMM), we cover the pharmacologic mechanisms underlying active therapies such as immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), traditional chemotherapy, and Venetoclax. We then review the clinical data supporting the use of these therapies, organized based on drug resistance\/refractoriness, and the role of autologous stem cell transplant (ASCT). Approaches to special situations during relapse such as renal impairment and extramedullary disease are also covered. Lastly, we look towards the future by briefly reviewing the clinical data supporting the use of chimeric antigen receptor (CAR-T) therapy, bispecific T cell engagers (BITE), and Cereblon E3 Ligase Modulators (CELMoDs).<\/jats:p>","DOI":"10.3390\/curroncol30020179","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:12:26Z","timestamp":1676437946000},"page":"2322-2347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Relapsed\/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse"],"prefix":"10.3390","volume":"30","author":[{"given":"Parva","family":"Bhatt","sequence":"first","affiliation":[{"name":"Tufts University Medical Center, Boston, MA 02145, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Kloock","sequence":"additional","affiliation":[{"name":"Tufts University Medical Center, Boston, MA 02145, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Comenzo","sequence":"additional","affiliation":[{"name":"Tufts University Medical Center, Boston, MA 02145, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard.2008.092031","article-title":"Disease severity in children and adolescents with Familial Mediterranean Fever: A comparative study to explore environmental effects on a monogenic disease","volume":"68","author":"Ozen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration","volume":"71","author":"Hoffmann","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","article-title":"Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects","volume":"69","author":"Chen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBPbeta translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Calabrese","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.molcel.2007.06.001","article-title":"DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase","volume":"26","author":"Lee","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1096\/fj.15-274050","article-title":"A novel effect of thalidomide and its analogs: Suppression of cereblon ubiquitination enhances ubiquitin ligase function","volume":"29","author":"Liu","year":"2015","journal-title":"FASEB J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/emboj\/16.8.2004","article-title":"Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation","volume":"16","author":"Morgan","year":"1997","journal-title":"EMBO J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20031571","article-title":"Aiolos Is Required for the Generation of High Affinity Bone Marrow Plasma Cells Responsible for Long-Term Immunity","volume":"199","author":"Georgopoulos","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1038\/s41467-021-25634-z","article-title":"The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling","volume":"12","author":"Shen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-017-0529-5","article-title":"Role of protein kinases CK1\u03b1 and CK2 in multiple myeloma: Regulation of pivotal survival and stress-managing pathways","volume":"10","author":"Manni","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"632399","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs","volume":"12","author":"Prince","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.3324\/haematol.2017.178947","article-title":"Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance","volume":"103","author":"Danhof","year":"2018","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma","volume":"2","author":"Morgan","year":"2006","journal-title":"Clin. Risk Manag."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: Final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-kappaB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2016.08.005","article-title":"NF-kappaB dysregulation in multiple myeloma","volume":"39","author":"Matthews","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","article-title":"Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.clml.2015.07.642","article-title":"CD38 Monoclonal Antibody Therapies for Multiple Myeloma","volume":"15","author":"Wong","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/mabs.29670","article-title":"Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer","volume":"6","author":"Meyer","year":"2014","journal-title":"mAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino, M., Innorcia, S., Boccadoro, M., and Bringhen, S. (2020). Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218192"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","article-title":"Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family","volume":"167","author":"Bouchon","year":"2001","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cts.12532","article-title":"Mechanisms of Action and Clinical Development of Elotuzumab","volume":"11","author":"Ritchie","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The Cytotoxicity Receptor CRACC (CS-1) Recruits EAT-2 and Activates the PI3K and Phospholipase C\u03b3 Signaling Pathways in Human NK Cells1","volume":"175","author":"Tassi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_50","first-page":"2649","article-title":"EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing\u2019s sarcoma EWS\/FLI1 fusion gene","volume":"13","author":"Thompson","year":"1996","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: Integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2022.2076847","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: Final results of the LYRA study","volume":"63","author":"Yimer","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Mark","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_55","unstructured":"Gold, J.M., and Raja, A. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_56","unstructured":"Ogino, M.H., and Tadi, P. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_57","unstructured":"Johnson-Arbor, K., and Dubey, R. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_58","unstructured":"Reyhanoglu, G., and Tadi, P. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_60","first-page":"212574","article-title":"Venetoclax: Evidence to date and clinical potential","volume":"8","author":"Desai","year":"2019","journal-title":"Drugs Context"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"a036400","DOI":"10.1101\/cshperspect.a036319","article-title":"BAX, BAK, and BOK: A Coming of Age for the BCL-2 Family Effector Proteins","volume":"12","author":"Moldoveanu","year":"2020","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_63","unstructured":"FDA (2023, February 01). Selinexor, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2021.1923473","article-title":"Selinexor for the treatment of patients with previously treated multiple myeloma","volume":"14","author":"Mo","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","article-title":"NESdb: A database of NES-containing CRM1 cargoes","volume":"23","author":"Xu","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","article-title":"Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death","volume":"9","author":"Argueta","year":"2018","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions","volume":"10","author":"Ganzetti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","article-title":"Mechanisms of lenalidomide sensitivity and resistance","volume":"91","author":"Karsan","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejh.13706","article-title":"Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics","volume":"108","author":"Richardson","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A.K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., and Mateos, M.V. (2022). Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J. Clin. Oncol.","DOI":"10.1200\/JCO.21.02734"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs. bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., and Raab, M.S. (2022). Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J. Clin. Oncol.","DOI":"10.1200\/JCO.21.02815"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106576","DOI":"10.1016\/j.leukres.2021.106576","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis","volume":"104","author":"Bringhen","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26480","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone +\/\u2212 subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial","volume":"97","author":"Terpos","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","article-title":"Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups","volume":"19","author":"Orlowski","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2021-149423","article-title":"Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011\/HOVON114 Trial","volume":"138","author":"Sonneveld","year":"2021","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-140934","article-title":"Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg\/m2 and Dexamethasone Plus\/Minus Cyclophosphamide in Relapsed and\/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)","volume":"136","author":"Mateos","year":"2021","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_108","unstructured":"(2023, February 01). GSK. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep\/."},{"key":"ref_109","unstructured":"FDA (2023, February 01). Teclistamab, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1703240","article-title":"DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma","volume":"28","author":"Lazzarino","year":"2001","journal-title":"Bone Marrow Transpl."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: Results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2018-99-111203","article-title":"Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide\/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse","volume":"132","author":"Goldschmidt","year":"2018","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.15782","article-title":"The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"185","author":"Cook","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-99-119762","article-title":"Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma","volume":"132","author":"Baertsch","year":"2018","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41375-020-1005-8","article-title":"Salvage second transplantation in relapsed multiple myeloma","volume":"35","author":"Dhakal","year":"2021","journal-title":"Leukemia"},{"key":"ref_123","unstructured":"Vakiti, A., Padala, S.A., and Mewawalla, P. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_124","first-page":"207","article-title":"Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival","volume":"56","author":"Abbott","year":"2001","journal-title":"Clin. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bozic, B., Rutner, J., Zheng, C., Ruckser, R., Selimi, F., Racz, K., Kocher, M., Tatzreiter, G., and Sebesta, C. (2021). Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. Cancers, 13.","DOI":"10.3390\/cancers13205036"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"20406207221088458","DOI":"10.1177\/20406207221088458","article-title":"An overview of treatment options for patients with relapsed\/refractory multiple myeloma and renal impairment","volume":"13","author":"Dimopoulos","year":"2022","journal-title":"Adv. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"107","author":"Capra","year":"2022","journal-title":"Haematologica"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5045\/br.2020.55.1.65","article-title":"Daratumumab in dialysis-dependent multiple myeloma","volume":"55","author":"Jeyaraman","year":"2020","journal-title":"Blood Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s11845-018-1951-6","article-title":"Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure","volume":"188","author":"Smyth","year":"2019","journal-title":"Ir. J. Med. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-140322","article-title":"Daratumumab with Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study","volume":"136","author":"Kastritis","year":"2020","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Antlanger, M., Dust, T., Reiter, T., Bohm, A., Lamm, W.W., Gornicec, M., Willenbacher, E., Nachbaur, D., Weger, R., and Rabitsch, W. (2018). Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: A multi-center, retrospective cohort study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4926-0"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41409-022-01657-y","article-title":"Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: A safe and effective option","volume":"57","author":"Lazana","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2014.226","article-title":"Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure","volume":"50","author":"Chodirker","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transpl."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","article-title":"The lymphoma-like polychemotherapy regimen \"Dexa-BEAM\" in advanced and extramedullary multiple myeloma","volume":"93","author":"Rasche","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Zhou, X., Fluchter, P., Nickel, K., Meckel, K., Messerschmidt, J., Bockle, D., Knorz, S., Steinhardt, M.J., Krummenast, F., and Danhof, S. (2020). Carfilzomib Based Treatment Strategies in the Management of Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease. Cancers, 12.","DOI":"10.3390\/cancers12041035"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Li, Z., Qiu, Y., Personett, D., Huang, P., Edenfield, B., Katz, J., Babusis, D., Tang, Y., Shirely, M.A., and Moghaddam, M.F. (2013). Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071754"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.12404","article-title":"Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains","volume":"162","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: Long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Martin, T., Usmani, S.Z., Berdeja, J.G., Agha, M., Cohen, A.D., Hari, P., Avigan, D., Deol, A., Htut, M., and Lesokhin, A. (2022). Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J. Clin. Oncol.","DOI":"10.1200\/JCO.22.00842"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_157","first-page":"16","article-title":"First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2021-147812","article-title":"CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1\/2 Study CC-92480-MM-002","volume":"138","author":"Richardson","year":"2021","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/OTT.S305429","article-title":"Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date","volume":"15","author":"Mann","year":"2022","journal-title":"Onco Targets Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:30Z","timestamp":1760121390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":159,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["curroncol30020179"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30020179","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}